ResMed Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? ResMed Inc. trades at $220 (market cap $32.61B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: ResMed Inc. pays a 1.17% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and ResMed Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| RMD | VCIT | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | Fixed Income |
52-Week High | $293.73 | $84.82 |
52-Week Low | $182.82 | $81.07 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →